ANI Pharmaceuticals acquires Alimera Sciences for $381m, adding Iluvien and Yutiq products for rare diseases.
ANI Pharmaceuticals acquires Alimera Sciences for $381m, boosting its rare disease portfolio. The deal includes Alimera's two commercial products, Iluvien and Yutiq, used in treating diabetic macular edema and chronic non-infectious uveitis. The transaction is expected to close in Q3 2024 and is valued at a 75% premium over Alimera's closing share price on Friday. ANI anticipates high single-digit to low double-digit accretion in adjusted earnings per share by 2025, with substantial growth thereafter.
June 24, 2024
7 Articles